A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Norbert Vey 1, 2 , Lionel Karlin 3 , Sophie Sadot-Lebouvier 4 , Florence Broussais 1 , Dominique Berton-Rigaud 4 , Jérôme Rey 1 , Aude Charbonnier 1 , Delphine Marie 5 , Pascale André 5 , Carine Paturel 5 , Robert Zerbib 5 , Jaafar Bennouna 4 , Gilles Salles 3 and Anthony Gonçalves 1, 2 1 Institut Paoli-Calmettes, Marseille, France 2 Aix-Marseille Université, Marseille, France 3 Centre Hospitalier Universitaire de Lyon Sud, Service d’Hématologie, Pierre Bénite, France 4 Institut de Cancérologie de l’Ouest–Site René Gauducheau, St Herblain, France 5 Innate Pharma, Marseille, France Correspondence to: Norbert Vey, email: veyn@ipc.unicancer.fr Keywords: monoclonal antibody; cancer immunotherapy; toxicity; natural killer cells Received: October 05, 2017 Accepted: March 02, 2018 Published: April 03, 2018 ABSTRACT Purpose: Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the safety of the anti-KIR2D mAb lirilumab in patients with various cancers. Experimental design: Thirty-seven patients with hematological malignancies ( n = 22) or solid tumors ( n = 15) were included in the study. Dose escalation (0.015 to 10 mg/kg) was conducted following a 3 + 3 design. Patients were scheduled to receive four cycles of treatment. In a second (extension) phase 17 patients were treated at 0.015 ( n = 9) or 3 mg/kg ( n = 8). Results: No dose-limiting toxicity was recorded. The most frequent lirilumab-related adverse events were pruritus (19%), asthenia (16%), fatigue (14%), infusion-related reaction (14%), and headache (11%), mostly mild or moderate. Pharmacokinetics was dose-dependent and linear, with minimal accumulation resulting from the 4-weekly repeated administrations. Full KIR occupancy (>95%) was achieved with all dosages, and the duration of occupancy was dose-related. No significant changes were observed in the number or distribution of lymphocyte subpopulations, nor was any reduction in the distribution of KIR2D-positive NK cells. Conclusions: This phase 1 trial demonstrated the satisfactory safety profile of lirilumab up to doses that enable full and sustained blockade of KIR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“In addition, hypomethylating drugs (5-azacytidine or decitabine) that are currently approved as treatments for AML and MDS have shown immunomodulatory effects, including enhanced production of Th1-type chemokines [26] and up-regulation of NKG2D ligand (MICA/B, ULBP) expression [27, 28].”
BackgroundGeneral Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380 · cited 13×
“The clinical relevance of KIR inhibition has been shown in allogeneic haplo-mismatched stem cell transplantation (alloSCT) in patients with AML.”
BackgroundInfluential
Cited by
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
Metadata
- Authors
- Vey, N., Karlin, L., Sadot-Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., Zerbib, R., Bennouna, J., Salles, G., & Gonçalves, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-03
- Volume
- 9
- Issue
- 25
- Pages
- 17675-17688
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2795441690
- Cited by
- 142
- References
- 5
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.